Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. The company is headquartered in Carlsbad, California and currently employs 8 full-time employees. The company went IPO on 2006-12-20. The firm is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The firm is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. The company utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.
Follow-Up Questions
Who is the CEO of Palisade Bio Inc?
Mr. J. D. Finley is the Chief Executive Officer of Palisade Bio Inc, joining the firm since 2021.
What is the price performance of PALI stock?
The current price of PALI is $0.6003, it has increased 0.38% in the last trading day.
What are the primary business themes or industries for Palisade Bio Inc?
Palisade Bio Inc belongs to Biotechnology industry and the sector is Health Care
What is Palisade Bio Inc market cap?
Palisade Bio Inc's current market cap is $5.4M
Is Palisade Bio Inc a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for Palisade Bio Inc, including 3 strong buy, 5 buy, 1 hold, 0 sell, and 3 strong sell
